Most Popular BioSpace (DHX) Headlines For May
5/28/2014 4:52:21 PM
June 2, 2014
Readers' most viewed stories for May 2014
In the blink of an eye, we're in June and we are officially halfway through 2014. The sun is shining, the birds are chirping, and summer is just around the corner. While most of you are finalizing your vacation plans, there have been some serious wheelings and dealings that took place in the biotech world. Although the month of April was monopolized by Novartis, May was engulfed by two drug giants from across the pond—AstraZeneca and Pfizer. It all began with the jaw-dropping news that Pfizer had its eye on AstraZeneca's pipeline and was willing to pay $117 billion for it. After much pulling and tugging, Astra decided to walk away on May 19th and remain independent for now.
From a clinical standpoint, Bristol-Myers wows the industry as it scored another breakthrough cancer drug title from the FDA. This is its second of the year (the first for a hep c drug), thus proving that the company has got some serious chops in their pipeline and is a force to be reckoned with.
May also proved to be a lucky month for Nurix. Backed by Third Rock Ventures, the San Francisco startup reeled in $25.1 million. The cash will fund Nurix's new drug discovery platform—the ubiquitin proteasome system. Just an FYI, the scientists who discovered the system won the Nobel Prize in 2004 so Nurix should definitely be a company on your watchlist.
Now, please see below for the popular stories in May. The top 10 stories reached nearly 50,000 views by the Biospace audience.
Thank you for being loyal readers!
10. AstraZeneca Rejects Pfizer's Final Offer
9. Merrimack Heads To The FDA As CA Drug Succeeds In Ph3 Trial
8. San Francisco Biotech Startup Nurix Taps $25.1 Million Financing
7. Novartis' Heart Drug Rejected By FDA
6. Gilead Shareholders Decimate Plan To Tie CEO Compensation To Drug Access
5. Pfizer Scores Another Win As Tofacitinib Succeeds In Ph3 Study
4. FDA Declares Bristol-AbbVie's Investigational Drug Elotuzumab A Breakthrough
3. Pfizer's U.S. R&D Jobs Jeopardized By Promises To UK For AstraZeneca Merger
2. New Filings Reveal How Pfizer Executives Made Millions Before Bid For AstraZeneca
1. Loophole Offers Pfizer A Risky Way Back Into A Deal With AstraZeneca
Help employers find you! Check out all the jobs and post your resume.
comments powered by